家庭抗惊厥药用于癫痫持续状态二线治疗的疗效
本研究基于ESETT试验数据,比较了苯二氮䓬难治性惊厥性癫痫持续状态患者接受家庭方案内或方案外二线抗惊厥药的结局。主要终点(60分钟临床发作停止且意识改善)无显著差异,但病历裁定结局显示非家庭药物与发作停止相关。
要点
- 接受家庭方案内二线药与方案外药的主要终点无显著差异。
- 病历裁定结局显示非家庭药物与发作停止相关(OR 0.52)。
- 研究未发现左乙拉西坦与家庭左乙拉西坦的交互作用。
核心结论
- 接受家庭方案内二线抗惊厥药与方案外药相比,主要终点无显著差异。
- 回顾性评估提示接受非家庭药物与发作停止相关。
研究设计与样本
- 基于ESETT试验数据的二次分析,纳入462例苯二氮䓬难治性惊厥性癫痫持续状态患者。
- 比较分配至家庭方案内研究药与方案外研究药的患者,采用IPTW逻辑回归。
主要发现
- 主要终点在家庭药组为39/89(44%),非家庭药组为76/143(53%),IPTW OR 0.66(95%CI 0.39-1.14)。
- 病历裁定结局在家庭药组为37/89(42%),非家庭药组为82/143(57%),IPTW OR 0.52(95%CI 0.30-0.89)。
- 研究药左乙拉西坦与家庭左乙拉西坦无交互作用,不良事件无差异。
临床怎么用
- 对于苯二氮䓬难治性惊厥性癫痫持续状态,选择二线抗惊厥药时不必因患者家庭用药而排除该药。
- 非家庭二线药物可能与更高的发作停止率相关,但需进一步验证。
局限性
- 本研究为基于ESETT试验数据的回顾性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether receiving a second-line anticonvulsant medication that is part of a patient's home regimen influences outcomes in benzodiazepine-refractory convulsive status epilepticus. METHODS: Using the Established Status Epilepticus Treatment Trial data, allocation to a study drug included in the patient's home anticonvulsant medication regimen was compared to receipt of an alternative second-line study medication. The primary outcome was cessation of clinical seizures with improved consciousness by 60 minutes after study drug initiation. Secondary outcomes were seizure cessation adjudicated from medical records and adverse events. We performed inverse probability of treatment-weighted (IPTW) logistic regressions. RESULTS: Of 462 patients, 232 (50%) were taking 1-2 of the 3 study medications at home. The primary outcome was observed in 39/89 (44%) patients allocated to their home medication vs 76/143 (53%) allocated to a nonhome medication (IPTW odds ratio [OR] 0.66, 95% confidence interval [CI] 0.39-1.14). The adjudicated outcome occurred in 37/89 (42%) patients vs 82/143 (57%), respectively (IPTW OR 0.52, 95% CI 0.30-0.89). There was no interaction between study levetiracetam and home levetiracetam and there were no differences in adverse events. CONCLUSION: There was no difference in the primary outcome for patients who received a home medication vs nonhome medication. However, the retrospective evaluation suggested an association between receiving a nonhome medication and seizure cessation. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with refractory convulsive status epilepticus, use of a home second-line anticonvulsant compared to a nonhome anticonvulsant did not significantly affect the probability of stopping seizures.
引用
- Wabl R, Terman SW, Kwok M, et al. Efficacy of Home Anticonvulsant Administration for Second-Line Status Epilepticus Treatment. Neurology. 2021. PMID: 34187862. doi:10.1212/WNL.0000000000012414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。